54 results
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of our ordinary shares or pre-funded warrants
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
of disposition or excess distribution cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of our
8-K
EX-99.1
URGN
UroGen Pharma Ltd
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
chargebacks and first time estimated Medicare refunds for discarded drug, offset by non-patient purchases.
R&D Expense: Research and development … Jelmyto net revenues include gross-to-net unfavorability driven by higher 340b chargebacks and estimated Medicare refunds for discarded drugs, offset
8-K
EX-10.1
fhyy3
13 Jun 22
Departure of Directors or Certain Officers
4:55pm